Literature DB >> 6736979

Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.

O Muramoto, M Sugishita, K Ando.   

Abstract

Subcutaneous or intravenous administration of physostigmine improved the copying of geometric figures in three out of six patients with presumed Alzheimer's disease who showed a remarkable constructional disturbance. This improvement reached its maximum 30 to 60 minutes after the physostigmine administration. These results not only provide further evidence supporting the hypothesis that central cholinergic potentiation ameliorates some of the impairments of Alzheimer's disease, but implicate a possible important role of the cholinergic system in the integration of constructional praxis.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6736979      PMCID： PMC1027824          DOI： 10.1136/jnnp.47.5.485

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  14 in total

1.  Cerebral blood flow in dementia.

Authors:  V C Hachinski; L D Iliff; E Zilhka; G H Du Boulay; V L McAllister; J Marshall; R W Russell; L Symon
Journal:  Arch Neurol       Date:  1975-09

2.  Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex.

Authors:  M M Mesulam; G W Van Hoesen
Journal:  Brain Res       Date:  1976-06-04       Impact factor: 3.252

3.  Physostigmine in Alzheimer's disease.

Authors:  C M Smith; M Swash
Journal:  Lancet       Date:  1979-01-06       Impact factor: 79.321

4.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.

Authors:  O Muramoto; M Sugishita; H Sugita; Y Toyokura
Journal:  Arch Neurol       Date:  1979-08

6.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

Authors:  D M Bowen; C B Smith; P White; A N Davison
Journal:  Brain       Date:  1976-09       Impact factor: 13.501

7.  Basal forebrain and hypothalamic connection to frontal and parietal cortex in the Rhesus monkey.

Authors:  J Kievit; H G Kuypers
Journal:  Science       Date:  1975-02-21       Impact factor: 47.728

8.  Physostigmine: effects on cognition and affect in normal subjects.

Authors:  K L Davis; L E Hollister; J Overall; A Johnson; K Train
Journal:  Psychopharmacology (Berl)       Date:  1976-12-21       Impact factor: 4.530

9.  Effects of physostigmine and lecithin on memory in Alzheimer disease.

Authors:  B H Peters; H S Levin
Journal:  Ann Neurol       Date:  1979-09       Impact factor: 10.422

10.  Memory enhancement after physostigmine treatment in the amnesic syndrome.

Authors:  B H Peters; H S Levin
Journal:  Arch Neurol       Date:  1977-04
View more
  9 in total

Review 1.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

Review 2.  Physostigmine for Alzheimer's disease.

Authors:  F Coelho; J Birks
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  Beneficial effect of physostigmine on clinical amnesic behaviour and neuropsychological test results in a patient with a post-encephalitic amnesic syndrome.

Authors:  C E Catsman-Berrevoets; F Van Harskamp; A Appelhof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

4.  The metabolic brain pattern of young subjects given scopolamine.

Authors:  R M Cohen; M Gross; W E Semple; T E Nordahl; T Sunderland
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

5.  Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.

Authors:  L Gustafson; L Edvinsson; N Dahlgren; B Hagberg; J Risberg; I Rosén; H Fernö
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 6.  Potential role of muscarinic agonists in Alzheimer's disease.

Authors:  E E Avery; L D Baker; S Asthana
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 7.  Neuroimaging in Alzheimer's disease: relevance for treatment.

Authors:  C H van Dyck
Journal:  Curr Psychiatry Rep       Date:  2001-02       Impact factor: 5.285

8.  Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.

Authors:  S D Provan; M D Miyamoto
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 9.  Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee.

Authors:  M Swash; D N Brooks; N E Day; C D Frith; R Levy; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.